In the claims:

Please amend claims 23, 25, 27, 29, 33-36, 39, 40, 43, 44, 47, 48, 60-67, 72-74, 77, 78, 81, 82, 85 and 86 as follows.

D2 3. ~~23.~~ (Once Amended) The polypeptide of claim ~~22~~ 2, wherein the amino acid sequence is fused to a heterologous polypeptide.

D3 5. ~~25.~~ (Once Amended) The polypeptide of claim ~~24~~ 4, wherein the amino acid sequence is fused to a heterologous polypeptide.

D4 7. ~~27.~~ (Once Amended) The polypeptide of claim ~~26~~ 6, wherein the amino acid sequence is fused to a heterologous polypeptide.

D5 9. ~~29.~~ (Once Amended) The polypeptide of claim ~~28~~ 8, wherein the amino acid sequence is fused to a heterologous polypeptide.

D6 10. ~~33.~~ (Once Amended) The polypeptide of claim ~~22~~ 21, wherein the amino acid sequence is fused to a heterologous polypeptide.

D7 11. ~~34.~~ (Twice Amended) An isolated polypeptide comprising a first amino acid sequence that is at least 95% identical to a second amino acid sequence selected from the group consisting of:

(a) amino acids 1 to 381 of SEQ ID NO:2;

(b) amino acids 2 to 381 of SEQ ID NO:2;

D7 cont'd

(c) amino acids 25 to 381 of SEQ ID NO:2; and

(d) a polypeptide fragment of SEQ ID NO:2,

wherein said polypeptide or polypeptide fragment stimulates cellular proliferation.

---

12. ~~35.~~ (Once Amended) The polypeptide of claim ~~34~~ 11, wherein said second amino acid sequence is (a).

D8

---

13. ~~36.~~ (Once Amended) The polypeptide of claim ~~35~~ 12, wherein the amino acid sequence is fused to a heterologous polypeptide.

---

14. ~~39.~~ (Once Amended) The polypeptide of claim ~~34~~ 11, wherein said second amino acid sequence is (b).

D9

---

15. ~~40.~~ (Once Amended) The polypeptide of claim ~~39~~ 14, wherein the amino acid sequence is fused to a heterologous polypeptide.

---

16. ~~43.~~ (Once Amended) The polypeptide of claim ~~34~~ 11, wherein said second amino acid sequence is (c).

D10

---

17. ~~44.~~ (Once Amended) The polypeptide of claim ~~43~~ 16, wherein the amino acid sequence is fused to a heterologous polypeptide.

---

18. ~~47.~~ (Once Amended) The polypeptide of claim ~~34~~ 11, wherein said second amino acid sequence is (d).

D 11

19. ~~48.~~ (Once Amended) The polypeptide of claim ~~47~~ 18, wherein the amino acid sequence is fused to a heterologous polypeptide.

20. ~~59.~~ (Once Amended) The polypeptide of claim ~~58~~ 20, wherein said amino acid sequence is (a).

22. ~~61.~~ (Once Amended) The polypeptide of claim ~~60~~ 21, wherein the amino acid sequence is fused to a heterologous polypeptide.

23. ~~62.~~ (Once Amended) The polypeptide of claim ~~59~~ 20, wherein said amino acid sequence is (b).

D 12

24. ~~63.~~ (Once Amended) The polypeptide of claim ~~62~~ 23, wherein the amino acid sequence is fused to a heterologous polypeptide.

25. ~~64.~~ (Once Amended) The polypeptide of claim ~~59~~ 20, wherein said amino acid sequence is (c).

26. ~~65.~~ (Once Amended) The polypeptide of claim ~~64~~ 25, wherein the amino acid sequence is fused to a heterologous polypeptide.

27. 20.
~~66~~. (Once Amended) The polypeptide of claim ~~59~~, wherein said amino acid sequence is (d).

D 12 cont'd

28 27
~~67~~. (Once Amended) The polypeptide of claim ~~66~~, wherein the amino acid sequence is fused to a heterologous polypeptide.

---

29 ~~72~~. (Twice Amended) An isolated polypeptide comprising a first amino acid sequence that is at least 95% identical to a second amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of the full-length polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75904;

D 13

(b) the amino acid sequence of the full-length polypeptide, lacking the N-terminal methionine, encoded by the human cDNA contained in ATCC Deposit Number 75904;

(c) the amino acid sequence of the mature polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75904; and

(d) a polypeptide fragment of the polypeptide encoded by the human cDNA contained in ATCC Deposit Number 75904;

wherein said polypeptide or polypeptide fragment stimulates cellular proliferation.

---

30 ~~73~~. (Once Amended) The polypeptide of claim ~~72~~ 29, wherein said second amino acid sequence is (a).

D 14

52

D

D14

31. (Once Amended) The polypeptide of claim 30, wherein the amino acid sequence is fused to a heterologous polypeptide.

32. (Once Amended) The polypeptide of claim 29, wherein said second amino acid sequence is (b).

D15

33. (Once Amended) The polypeptide of claim 32, wherein the amino acid sequence is fused to a heterologous polypeptide.

34. (Once Amended) The polypeptide of claim 29, wherein said second amino acid sequence is (c).

D16

35. (Once Amended) The polypeptide of claim 34, wherein the amino acid sequence is fused to a heterologous polypeptide.

36. (Once Amended) The polypeptide of claim 29, wherein said second amino acid sequence is (d).

D17

37. (Once Amended) The polypeptide of claim 36, wherein the amino acid sequence is fused to a heterologous polypeptide.